LEUKEMIA, MYELOID, ACUTE

This early-stage study tests a new drug called bleximenib combined with standard leukemia treatments for people with acute myeloid leukemia (AML) that has specific genetic changes (KMT2A or NPM1). The main goals are to find the best dose and check for side effects. About 196 part…

This study tests two experimental drug combinations for adults newly diagnosed with a specific genetic subtype of acute myeloid leukemia (IDH-mutant AML) who cannot tolerate intensive chemotherapy. Participants receive either one of two oral targeted pills (AG-120 or AG-221) plus…

This study tests whether adding the targeted drug ivosidenib to standard azacitidine helps adults with a specific genetic form of acute myeloid leukemia (IDH1-mutated AML) who cannot receive intensive chemotherapy. About 146 participants received either the combo or a placebo plu…

This study tests an oral chemotherapy drug (azacitidine) as maintenance therapy for Chinese adults with acute myeloid leukemia who are already in complete remission. The goal is to see if taking this pill can help prevent the cancer from coming back longer than best supportive ca…

This early-stage study tests a new drug, JNJ-89853413, in 64 people whose acute myeloid leukemia (AML) or myelodysplastic neoplasms (MDS) have returned or stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can he…

This study tests a program that combines mindfulness and music therapy, delivered through an app or website, for people undergoing a stem cell transplant. The goal is to see if it helps improve quality of life and reduce symptoms like pain. About 60 adults with certain blood canc…

This study follows people with different cancers who have already received treatment in an earlier study. The main goal is to track serious side effects and other health issues over time. No new treatment is given; participants are simply monitored for safety.